接受长期抗病毒治疗的亚洲慢性乙型肝炎患者与匹配对照的死亡率相当:一项基于人群的研究
该研究基于韩国国民健康保险服务数据库,纳入接受抗病毒治疗≥3年、年龄40-64岁的慢性乙型肝炎患者,并与倾向评分匹配的无慢性乙型肝炎普通人群比较。中位随访7.2年,抗病毒治疗组与匹配普通人群的全因死亡率无显著差异(aHR 0.96,95%CI 0.83-1.10;P=0.51),心血管疾病风险更低(aHR 0.70,95%CI 0.62-0.79;P<0.001),肝细胞癌风险更高(aHR 13.16,95%CI 10.90-15.89;P<0.001),非肝细胞癌恶性肿瘤风险相当(aHR 1.05,95%CI 0.98-1.13;P=0.137)。
要点
- 接受长期抗病毒治疗的慢性乙型肝炎患者全因死亡率与匹配普通人群相当(aHR 0.96,95%CI 0.83-1.10)。
- 抗病毒治疗组心血管疾病风险低于匹配普通人群(aHR 0.70,95%CI 0.62-0.79)。
- 抗病毒治疗组肝细胞癌风险高于匹配普通人群(aHR 13.16,95%CI 10.90-15.89),非肝细胞癌恶性肿瘤风险相当。
核心结论
- 接受抗病毒治疗的慢性乙型肝炎患者全因死亡率和非肝细胞癌恶性肿瘤风险与匹配普通人群相似,心血管疾病风险更低。
研究设计与样本
- 基于韩国国民健康保险服务数据库的人群研究,纳入2011至2012年间接受健康检查、年龄40-64岁、接受抗病毒治疗≥3年的慢性乙型肝炎患者(抗病毒治疗组),并从无慢性乙型肝炎人群中倾向评分匹配普通人群作为对照。
主要发现
- 中位随访7.2年,抗病毒治疗组26467例,匹配普通人群75469例。
- 抗病毒治疗组5年和7年累积全因死亡率分别为0.40%和1.0%,匹配普通人群分别为0.50%和1.0%(aHR 0.96,95%CI 0.83-1.10;P=0.51)。
- 抗病毒治疗组心血管疾病风险低于匹配普通人群(aHR 0.70,95%CI 0.62-0.79;P<0.001)。
- 抗病毒治疗组肝细胞癌风险高于匹配普通人群(aHR 13.16,95%CI 10.90-15.89;P<0.001)。
- 抗病毒治疗组非肝细胞癌恶性肿瘤风险与匹配普通人群相当(aHR 1.05,95%CI 0.98-1.13;P=0.137)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Antiviral therapy (AVT) substantially improved the prognosis for patients with chronic hepatitis B (CHB). Head-to-head comparisons of prognosis between treated patients with CHB and the general population are scarce. We directly compared the prognosis between Asian patients with CHB receiving AVT and the general population. METHODS: From the South Korean National Health Insurance Service database, patients with CHB receiving AVT ≥3 years, aged 40-64 years, who underwent health examinations between 2011 and 2012 (AVT-CHB group) were recruited. As a control, propensity score-matched general population was chosen among patients without CHB. The primary outcome was all-cause mortality; secondary outcomes were cardiovascular disease (CVD), hepatocellular carcinoma (HCC), and all types of non-HCC malignancies. RESULTS: During follow-up (median 7.2 years), 26,467 and 75,469 individuals in the AVT-CHB group and matched general population were analyzed. The 5- and 7-year cumulative all-cause mortality rates were 0.40% and 1.0% for the AVT-CHB group vs 0.50% and 1.0% for the matched general population (adjusted hazard ratio [aHR] 0.96, 95% confidence interval [CI] 0.83-1.10; P = 0.51). The AVT-CHB group had a lower risk of CVD than the matched general population (aHR 0.70, 95% CI: 0.62-0.79; P < 0.001). Although the AVT-CHB group was more likely to develop HCC than the matched general population (aHR 13.16, 95% CI: 10.90-15.89; P < 0.001), the non-HCC malignancy risks in the AVT-CHB group were comparable to the matched general population (aHR 1.05, 95% CI 0.98-1.13; P = 0.137). DISCUSSION: The AVT-CHB group had a similar risk of all-cause mortality and non-HCC malignancies and a lower risk of CVD than the matched general population.
引用
- Yun B, Oh J, Ahn SH, et al. Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study. Am J Gastroenterol. 2022. PMID: 36288330. doi:10.14309/ajg.0000000000002074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。